TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
Ralph J. A. Maas(Radboud University Nijmegen), Harry Dolstra(Radboud University Nijmegen), Nicolaas Schaap(Radboud University Nijmegen), Jolien M.R. Van der Meer(Sanquin), Joop H. Jansen(Radboud University Nijmegen), Vera Mekers(Radboud University Nijmegen), Alan J. Korman(Bristol-Myers Squibb (Germany)), Leon F.A.G. Massuger(Radboud University Nijmegen), Rob Woestenenk(Radboud University Nijmegen), Willemijn Hobo(Maastricht University Medical Centre), Paul K.J.D. de Jonge(Radboud University Nijmegen), Jeannette Cany, Somayeh Rezaeifard(Radboud University Nijmegen), Janneke S. Hoogstad‐van Evert(Radboud University Nijmegen)
Cited by 69
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k